Role of Family History of Sudden Death in Risk Stratification and Prevention of Sudden Death With Implantable Defibrillators in Hypertrophic Cardiomyopathy

被引:77
|
作者
Bos, J. Martijn [2 ]
Maron, Barry J.
Ackerman, Michael J. [1 ,2 ,3 ]
Haas, Tammy S. [4 ]
Sorajja, Paul [1 ]
Nishimura, Rick A. [1 ]
Gersh, Bernard J. [1 ]
Ommen, Steve R. [1 ]
机构
[1] Mayo Clin, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA
[3] Mayo Clin, Dept Pediat, Div Pediat Cardiol, Rochester, MN USA
[4] Minneapolis Heart Inst Fdn, Hypertroph Cardiomyopathy Ctr, Minneapolis, MN USA
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2010年 / 106卷 / 10期
关键词
LEFT-VENTRICULAR HYPERTROPHY; OUTFLOW TRACT OBSTRUCTION; CARDIAC DEATH; CARDIOVERTER-DEFIBRILLATORS; CLINICAL-COURSE; UNITED-STATES; MANAGEMENT; EPIDEMIOLOGY; ASSOCIATION; ARRHYTHMIAS;
D O I
10.1016/j.amjcard.2010.06.077
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The selection of patients with hypertrophic cardiomyopathy (HC) for the primary prevention of sudden death (SD) with implantable cardioverter-defibrillators (ICDs) has been determined by the assessment of 5 risk factors. We examined one of these markers, the family history of HC-related SD in first-degree relatives, for which few data are available. The rate of appropriate ICD interventions was assessed in 177 consecutive patients with HC (63% men, age 45 +/- 14 years) who had undergone prophylactic implantation at 2 tertiary centers, according to the identification of >= 1 risk markers. During a follow-up period of 4.6 +/- 3 years, 25 patients (14%) had experienced appropriate ICD interventions for ventricular tachycardia/fibrillation. The patients with a risk profile that included a family history of SD experienced interventions at a similar rate (3.7/100 person-years) as the patients without a family history of SD (3.1/100 person-years, p = 0.2). The rate and frequency of appropriate ICD interventions in 42 patients who had undergone implantation solely because of a family history of SD was 2.2/100 person-years (4/42, 10%), similar to that for patients with one risk factor other than SD family history (3.4%/100 person-years; 7/50, 14%; p = 0.2) and patients with multiple risk factors with (4.5/100 person-years; 9/49, 18%) and without (3.5/100 person-years; 5/36, 14%) a family history of SD (p = 0.8). In conclusion, a family history of SD is an important risk marker in patients with HC. Patients receiving ICDs for primary prevention because of a family history of HC-related SD, whether as an isolated risk factor or combined with other markers, experienced rates of appropriate ICD discharge comparable to that of other patient subsets with increased risk. (C) 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 2010;106:1481-1486)
引用
收藏
页码:1481 / 1486
页数:6
相关论文
共 50 条
  • [1] Risk stratification and role of implantable defibrillators for prevention of sudden death in children with hypertrophic cardiomyopathy
    Ziolkowska, L.
    Kawalec, W.
    Turska-Kmiec, A.
    Boruc, A.
    Daszkowska, J.
    Bieganowska, K.
    Kowalczyk, M.
    EUROPEAN HEART JOURNAL, 2011, 32 : 593 - 593
  • [2] Risk Stratification and Role of Implantable Defibrillators for Prevention of Sudden Death in Patients With Hypertrophic Cardiomyopathy
    Maron, Barry J.
    CIRCULATION JOURNAL, 2010, 74 (11) : 2271 - 2282
  • [3] Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy
    Maron, Barry J.
    Spirito, Paolo
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2008, 19 (10) : 1118 - 1126
  • [4] Important Role of Positive Family History of Sudden Death in Risk Stratification and Prevention of Death with the Implantable Defibrillator in Patients with Hypertrophic Cardiomyopathy
    Bos, J. M.
    Maron, Barry J.
    Ackerman, Michael J.
    Haas, Tammy S.
    Sorajja, Paul
    Nishimura, Rick A.
    Gersh, Bernard J.
    Ommen, Steve R.
    CIRCULATION, 2008, 118 (18) : S592 - S593
  • [5] Risk stratification and prevention of sudden death in hypertrophic cardiomyopathy
    Autore C.
    Quarta G.
    Spirito P.
    Current Treatment Options in Cardiovascular Medicine, 2007, 9 (6) : 431 - 435
  • [6] Sudden death in hypertrophic cardiomyopathy - Risk stratification and prevention
    Valgaeren, G
    Conraads, V
    Colpaert, C
    Rademakers, F
    Vrints, C
    ACTA CARDIOLOGICA, 1998, 53 (01) : 23 - 29
  • [7] Implantable cardioverter defibrillators for primary prevention of sudden death in hypertrophic cardiomyopathy
    Konstantinou, Dimitrios M.
    Efthimiadis, Georgios K.
    Vassilikos, Vassilios
    Paraskevaidis, Stylianos
    Pagourelias, Efstathios
    Maron, Barry J.
    Karvounis, Haralambos
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2016, 17 (06) : 433 - 439
  • [8] Risk of sudden death in patients with hypertrophic cardiomyopathy and a family history of sudden death
    Gardner, MJ
    Tome, M
    Thaman, R
    Sachdev, B
    Murphy, R
    Elliott, PM
    McKenna, WJ
    CIRCULATION, 2003, 108 (17) : 626 - 626
  • [9] Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy
    Maron, Barry J.
    Maron, Martin S.
    HEART RHYTHM, 2016, 13 (05) : 1155 - 1165
  • [10] Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy
    Maron, Barry J.
    Spirito, Paolo
    Shen, Win-Kuang
    Haas, Tammy S.
    Formisano, Francesco
    Link, Mark S.
    Epstein, Andrew E.
    Almquist, Adrian K.
    Daubert, James P.
    Lawrenz, Thorsten
    Boriani, Giuseppe
    Estes, N. A. Mark, III
    Favale, Stefano
    Piccininno, Marco
    Winters, Stephen L.
    Santini, Massimo
    Betocchi, Sandro
    Arribas, Fernando
    Sherrid, Mark V.
    Buja, Gianfranco
    Semsarian, Christopher
    Bruzzi, Paolo
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (04): : 405 - 412